Eradavir — Influenza Treatment RCT
Verified$250K
Funder
Recipient
Eradavir
Date
Mar 2025
Data source
Source
Notes
[Scientific Research] Open Philanthropy recommended an investment of $250,000 in Eradavir to support a randomized controlled trial of a drug for treating influenza. The team’s novel antiviral approach links two haptens that recruit the immune system to an already approved influenza antiviral, zanamivir, which binds to the neuraminidase protein found on the virus and infected cell. This follows our July 2023 investment and falls within our focus area of scientific research.
Other Grants by Coefficient Giving
2625| Grant | Recipient | Amount | Date |
|---|---|---|---|
| Janaagraha — Air Quality Grants Assessment | $195K | Dec 2024 | |
| Futurewise — Housing Advocacy in Washington | $450K | Apr 2023 | |
| Exscientia — Agonists for Interferon Lambda | $2.3M | Sep 2023 | |
| Kurzgesagt — Short-form Video Content | $3M | Mar 2022 | |
| Kurzgesagt — Video Production (2023) | $1.7M | May 2023 | |
| Kurzgesagt — Video Creation and Translation | $2.6M | Dec 2021 | |
| Lightcone Infrastructure – General Support | Lighthaven (Event Venue) | $4.5M | Sep 2022 |
| Lightcone Infrastructure — General Support (2023) | Lighthaven (Event Venue) | $3M | Oct 2023 |
| Conjecture — Cybersecurity Bootcamp | Conjecture | $223K | Jun 2025 |
| Conjecture — AI Safety Technical Program | Conjecture | $224K | May 2023 |
Showing 10 of 2625 grants